The Business of Biofabrication

In a significant move that bridges two of the world’s leading biotech ecosystems, Cellbricks Therapeutics, a Berlin-based tissue therapeutics pioneer, has launched a new U.S. subsidiary in Cambridge, Massachusetts. The event, marked by a ribbon-cutting ceremony, featured distinguished guests including Berlin’s Governing Mayor, Kai Wegner, Deputy Mayor and Senator for Economics, Franziska Giffey, and State Secretary for Research, Dr. Henry Marx. This expansion underscores the company’s ambition to drive global innovation in implantable cell therapies.

Image above of Cellbricks unique multi-DLP 3D bioprinter.

A Partnership with MIT’s The Engine

Coinciding with the launch, Cellbricks Therapeutics announced its acceptance into The Engine, MIT’s accelerator program designed for “Tough Tech” startups tackling complex, world-changing challenges. The company joins a group of innovators gaining access to the accelerator’s resources, mentorship, and cutting-edge infrastructure. Emily Knight, CEO and President of The Engine, welcomed Cellbricks Therapeutics, expressing enthusiasm for the company’s potential to impact the future of regenerative medicine.

Berlin Meets Boston: A Transatlantic Vision

With its dual presence in Berlin and Boston, Cellbricks Therapeutics aims to harness the unique strengths of both regions. Berlin offers a robust foundation in research and innovation, while Boston, often called the epicenter of biotechnology, provides access to talent, funding, and cutting-edge technology.

To reflect its growing commitment to regenerative medicine, the company announced a unified brand identity—Cellbricks Therapeutics—for all its operations. This rebranding emphasizes its focus on making cell therapy implantable and accessible to patients in need.

A Collaborative Milestone

The launch was made possible with the support of notable industry figures, including Dane C. and Johannes Fruehauf, whose contributions have been integral to Cellbricks’ transatlantic growth.

About Cellbricks Therapeutics

Cellbricks Therapeutics, originally founded in Berlin, is a regenerative medicine 3D bioprinting company. The company specializes in developing implantable cell therapies, leveraging advanced multi-DLP bioprinting technology.

About MIT’s The Engine

The Engine, built by MIT, is an accelerator program designed to support “Tough Tech” startups tackling the world’s most complex challenges in areas like biotechnology, energy, and materials science. Known as “The Home for Tough Tech,” The Engine provides its member companies with access to funding, mentorship, and state-of-the-art resources, enabling them to scale innovations and bring impactful technologies to market.